Arbor Biotechnologies (@arbortx) 's Twitter Profile
Arbor Biotechnologies

@arbortx

Genetic medicines for #geneticdiseases. Follow/like/retweet≠endorsement

ID: 1398335946895114242

linkhttp://arbor.bio calendar_today28-05-2021 17:55:24

528 Tweet

532 Takipçi

477 Takip Edilen

Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Thank you to our Board Member Chen Yu—Managing Partner at TCGX and Founding Director of ElevAAte and to our Heritage, Race & Nationality ERG for an engaging fireside chat on how cultural upbringing can empower, challenge, and shape professional growth. #ArborAware

Thank you to our Board Member Chen Yu—Managing Partner at TCGX and Founding Director of <a href="/ElevAAteBiotech/">ElevAAte</a> and to our Heritage, Race &amp; Nationality ERG for an engaging fireside chat on how cultural upbringing can empower, challenge, and shape professional growth.
 
#ArborAware
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re excited to be attending the Oxalosis and Hyperoxaluria Foundation’s Annual Patient and Family Summit! We'll be joining patients, families, and clinical experts to connect, learn, and work together toward making an impact for those affected by hyperoxaluria. Oxalosis & Hyperoxaluria Foundation

We’re excited to be attending the Oxalosis and Hyperoxaluria Foundation’s Annual Patient and Family Summit! We'll be joining patients, families, and clinical experts to connect, learn, and work together toward making an impact for those affected by hyperoxaluria.

<a href="/OHFTweet/">Oxalosis & Hyperoxaluria Foundation</a>
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re incredibly proud to celebrate our very own Dr. Yurong Xin, VP of Computational Biology & Data Science, who has been named one of Endpoints News’ LGBTQ+ Biopharma Leaders! Hear from Yurong and the 14 other incredible honorees here: bit.ly/4nDkbmD Endpoints News

We’re incredibly proud to celebrate our very own Dr. Yurong Xin, VP of Computational Biology &amp; Data Science, who has been named one of Endpoints News’ LGBTQ+ Biopharma Leaders!

Hear from Yurong and the 14 other incredible honorees here:
bit.ly/4nDkbmD

<a href="/endpts/">Endpoints News</a>
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Our CEO, Devyn Smith, joined life sciences leaders nationwide in calling on Congress to protect federal science funding. Sustained investment is critical to innovation, talent development, and maintaining U.S. leadership in health and technology. bit.ly/44bk0XV

Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re back from the Oxalosis and Hyperoxaluria Foundation's Annual Patient and Family Summit! The powerful stories, meaningful connections, and incredible strength of the PH1 community continue to drive our work toward better outcomes for patients and families. Oxalosis & Hyperoxaluria Foundation

We’re back from the Oxalosis and Hyperoxaluria Foundation's Annual Patient and Family Summit!

The powerful stories, meaningful connections, and incredible strength of the PH1 community continue to drive our work toward better outcomes for patients and families.

<a href="/OHFTweet/">Oxalosis & Hyperoxaluria Foundation</a>
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re proud to announce the first patient has been dosed in our redePHine Phase 1/2 study of ABO-101, an investigational CRISPR-based gene editing therapy for primary hyperoxaluria type 1 (PH1). Read more here: bit.ly/4lSoN6R

Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Our annual Field Day was full of laughs, surprising displays of athletic talent, and just the right amount of competitive energy! 🏆 #ArborHappengings

Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re excited to be sponsoring the International Symposium on Primary Hyperoxaluria, where Chief Medical Officer, Dan Ory will be sharing insight into our lead program, ABO-101.

We’re excited to be sponsoring the International Symposium on Primary Hyperoxaluria, where Chief Medical Officer, Dan Ory will be sharing insight into our lead program, ABO-101.
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

John Murphy and Tia DiTommaso joined CGTLive® at #ASGCT2025 to share preclinical evidence supporting our lead program, ABO-101, a potential one-time gene-editing therapy in development for primary hyperoxaluria type 1 (PH1). Watch here: bit.ly/3JUE5dk

Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re thrilled to be attending the Keystone Symposia on AI in Molecular Biology, where Jesse Tordoff will share how we’re advancing a compact, precise genome editor through the power of machine learning–guided protein engineering. Keystone Symposia

We’re thrilled to be attending the Keystone Symposia on AI in Molecular Biology, where Jesse Tordoff will share how we’re advancing a compact, precise genome editor through the power of machine learning–guided protein engineering. 

<a href="/KeystoneSymp/">Keystone Symposia</a>
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Today, our Chief Operating Officer, Pam Stetkiewicz, will be presenting at the Committee for Advanced Therapies (CAT) workshop on gene editing, where she will discuss the challenges in gene-editing drug development.

Today, our Chief Operating Officer, Pam Stetkiewicz, will be presenting at the Committee for Advanced Therapies (CAT) workshop on gene editing, where she will discuss the challenges in gene-editing drug development.
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re proud to be riding in the The ALS Association's Ride to Defeat ALS this Saturday! We ride to honor those who’ve lost their battle, celebrate those fighting, and move closer to a future without ALS. Every mile makes an impact—for patients, families, and the search for a cure.

We’re proud to be riding in the <a href="/alsassociation/">The ALS Association</a>'s Ride to Defeat ALS this Saturday!

We ride to honor those who’ve lost their battle, celebrate those fighting, and move closer to a future without ALS. Every mile makes an impact—for patients, families, and the search for a cure.
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Thank you to the The ALS Association for hosting our Arboriders for the second year at the Ride to Defeat ALS! Together, we pedaled, pushed, and powered forward for a world without ALS. #ArborCares

Thank you to the <a href="/alsassociation/">The ALS Association</a> for hosting our Arboriders for the second year at the Ride to Defeat ALS!

Together, we pedaled, pushed, and powered forward for a world without ALS.

#ArborCares
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Mike Kuefner will be presenting tomorrow at the 5th Annual Rare & Genetic Kidney Disease Drug Development Summit, sharing insight into ABO-101, a novel gene editing therapy for Primary Hyperoxaluria Type I.

Mike Kuefner will be presenting tomorrow at the 5th Annual Rare &amp; Genetic Kidney Disease Drug Development Summit, sharing insight into ABO-101, a novel gene editing therapy for Primary Hyperoxaluria Type I.
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

We’re excited to be attending the 2025 Cell & Gene Therapy Meeting on the Mesa! We look forward to connecting with industry leaders and contributing to the conversation on accelerating innovation and delivering transformative therapies to patients. Alliance for Regenerative Medicine (ARM) #CGMesa25

We’re excited to be attending the 2025 Cell &amp; Gene Therapy Meeting on the Mesa!

We look forward to connecting with industry leaders and contributing to the conversation on accelerating innovation and delivering transformative therapies to patients.

<a href="/alliancerm/">Alliance for Regenerative Medicine (ARM)</a> #CGMesa25
Arbor Biotechnologies (@arbortx) 's Twitter Profile Photo

Thrilled to announce our strategic collaboration with Chiesi Global Rare Diseases on the development of ABO-101 for #PH1 and additional #raredisease targets. Together, we are committed to bringing hope to patients & their families through meaningful innovation. Learn more: bit.ly/4mR417o